New glimmer: MediUni Vienna discovers revolutionary approach to liver diseases

New glimmer: MediUni Vienna discovers revolutionary approach to liver diseases

A groundbreaking study by the MedUni Vienna has uncovered a promising approach to the treatment of metabolic diseases of the liver. Research focused on the inhibition of the enzyme obesity triglyceride lipase (ATGL), which plays a key role in fat metabolism. In experimental tests, this not only led to an improvement in liver health, but also reduced liver fat and inflammation as well as the fibrotic conversion, as was published in the prestigious Journal of Hepatology. Researchers led by Emmanuel Dauda Dixon and Michael Trauner observed significant positive effects in mice that had previously received a high -fat diet and had developed a steatohepatitis -like disease using chemical intervention.

New therapeutic approach

The use of the specific enzyme inhibitor atli-Statin (Atgli) has a great impact: The study results showed an improvement in the PPARα signal path and promoting the synthesis of hydrophilic bile acids, which could revolutionize the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD), which according to experts increases and caused serious health problems. This disease can lead to liver cirrhosis and cancer, which is all the more urgent, as is reported in the further analysis of ATGL inhibition by PubMed, which deepened the progress in the mechanisms of mash (metabolic dysfunction-associated steatohepatitis) and liver fibrosis.

The study by Dixon and Trauner shows that the inhibition of ATGL also has favorable effects on bile acid composition and fat intake in the intestine. These findings open up new ways to develop innovative medication that could improve the life of millions of affected people. In view of the strongly increasing cases of Masld, which are often due to unhealthy lifestyles, this research is of crucial importance and may ring a new era in liver disease treatment.